Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2018

Open Access 01-12-2018 | Research article

Huatuo Zaizao pill ameliorates cognitive impairment of APP/PS1 transgenic mice by improving synaptic plasticity and reducing Aβ deposition

Authors: Jing-Hua Zhang, Lin-Jie Yu, Hui Yang, Zhen Hui, Su Jiang, Ling Chen, Yang Zhao, Su-Lei Wang, Yi Liu, Yun Xu

Published in: BMC Complementary Medicine and Therapies | Issue 1/2018

Login to get access

Abstract

Background

It is well known that Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by memory deficits and cognitive decline. Amyloid-β (Aβ) deposition and synaptic dysfunction play important roles in the pathophysiology of Alzheimer’s disease (AD). The Huatuo Zaizao pill (HT) is a Traditional Chinese Medicine (TCM) that has been used clinically for many years in China, mainly for post-stroke rehabilitation and cognitive decline; however, the mechanism of cognitive function is not clear. In this study, we investigated the effect of HT on hippocampal synaptic function, Amyloid-β (Aβ) deposition in APP/PS1 AD transgenic mice.

Method

Six-month-old APP/PS1 transgenic (Tg) mice were randomly divided into control, HT-treated, and memantine (MEM)-treated groups. Then, these groups were orally administered vehicle (for the control), HT (0.25 g/kg) and MEM (5 mg/kg) respectively for 4 weeks. The Morris water maze, Novel Object Recognition, and Open field tests were used to assess cognitive behavioral changes. We evaluated the effects of HT on neuronal excitability, membrane ion channel activity, and synaptic plasticity in acute hippocampal slices by combining electrophysiological extracellular tests. Synaptic morphology in the hippocampus was investigated by electron microscopy. Western blotting was used to assess synaptic-associated protein and Aβ production and degrading levels. Immunofluorescence staining was used to determine the relative integrated density.

Results

HT can ameliorate hippocampus-dependent memory deficits and improve synaptic dysfunction by reversing LTP impairment in APP/PS1 transgenic mice. Moreover, HT reduces amyloid plaque deposition by regulating α-secretase and γ-secretase levels.

Conclusion

HT can improve the learning and memory function of APP/PS1 transgenic mice by improving synaptic function and reducing amyloid plaque deposition.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alzheimer’s A. Alzheimer's disease facts and figures. Alzheimers Dement. 2015;11(3):332.CrossRef Alzheimer’s A. Alzheimer's disease facts and figures. Alzheimers Dement. 2015;11(3):332.CrossRef
2.
go back to reference Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer’s disease and its models. Neuroscience. 2013;251:51–65.CrossRefPubMed Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer’s disease and its models. Neuroscience. 2013;251:51–65.CrossRefPubMed
3.
go back to reference Wei L, Lv S, Huang Q, Wei J, Zhang S, Huang R, et al. Pratensein attenuates Abeta-induced cognitive deficits in rats: enhancement of synaptic plasticity and cholinergic function. Fitoterapia. 2015;101:208–17.CrossRefPubMed Wei L, Lv S, Huang Q, Wei J, Zhang S, Huang R, et al. Pratensein attenuates Abeta-induced cognitive deficits in rats: enhancement of synaptic plasticity and cholinergic function. Fitoterapia. 2015;101:208–17.CrossRefPubMed
4.
go back to reference Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361(6407):31.CrossRefPubMed Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361(6407):31.CrossRefPubMed
5.
go back to reference Li Z, Li H, Zhao C, Lv C, Zhong C, Xin W, et al. Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer&aposs Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation. CNS Neurol Disord Drug Targets. 2015;14(3):360–9.CrossRefPubMed Li Z, Li H, Zhao C, Lv C, Zhong C, Xin W, et al. Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer&aposs Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation. CNS Neurol Disord Drug Targets. 2015;14(3):360–9.CrossRefPubMed
6.
go back to reference Qu S, Wang T, Zhang J, X Sun PY, Kong L, et al. Effects of the coadministration of Huatuo Zaizao pills and aspirin on hemorrheology and blood coagulation in rabbits. Biomed Rep. 2013;1(3):459–63.CrossRefPubMedPubMedCentral Qu S, Wang T, Zhang J, X Sun PY, Kong L, et al. Effects of the coadministration of Huatuo Zaizao pills and aspirin on hemorrheology and blood coagulation in rabbits. Biomed Rep. 2013;1(3):459–63.CrossRefPubMedPubMedCentral
7.
go back to reference Wu KZ, Jiang YG, Zuo Y, Li AX. Establishment of the method for screening the potential targets and effective components of huatuo reconstruction pill. Interdiscip Sci. 2014;6(2):125–32.CrossRefPubMed Wu KZ, Jiang YG, Zuo Y, Li AX. Establishment of the method for screening the potential targets and effective components of huatuo reconstruction pill. Interdiscip Sci. 2014;6(2):125–32.CrossRefPubMed
8.
go back to reference Zheng YQ, Li L, Liu JX, Yao MJ, Liu SB, Si JX, et al. Study on effect of huatuo zaizao extractum on focal cerebral ischemia/reperfusion neurogenesis in rats and its mechanisms. Zhongguo Zhong Yao Za Zhi. 2014;39:891–5.PubMed Zheng YQ, Li L, Liu JX, Yao MJ, Liu SB, Si JX, et al. Study on effect of huatuo zaizao extractum on focal cerebral ischemia/reperfusion neurogenesis in rats and its mechanisms. Zhongguo Zhong Yao Za Zhi. 2014;39:891–5.PubMed
9.
go back to reference Zheng F. Clinical efficacy of Hua Tuo’s pill in the treatment of cerebral infarction. China Heal Stands Manageme. 2015;6(20):122–3. Zheng F. Clinical efficacy of Hua Tuo’s pill in the treatment of cerebral infarction. China Heal Stands Manageme. 2015;6(20):122–3.
10.
go back to reference Xia W, Lu YJ, Yuan DC, Kong DZ, Qi WC, Kang F. Efficacy of Huatuo Zaizao pills for ischemic stroke. Eval Anal Drug Hospit China. 2012;12:772–5. Xia W, Lu YJ, Yuan DC, Kong DZ, Qi WC, Kang F. Efficacy of Huatuo Zaizao pills for ischemic stroke. Eval Anal Drug Hospit China. 2012;12:772–5.
11.
go back to reference Cai YF, Xu Y, Guo JW, Zhang XC, Li WF, Liang WX, et al. The metaanalysis about the clinical efficacy of Huatuo Zaizao pills on ischemic stroke. Chin Tradit Herb Drug. 2007;4:581–4. Cai YF, Xu Y, Guo JW, Zhang XC, Li WF, Liang WX, et al. The metaanalysis about the clinical efficacy of Huatuo Zaizao pills on ischemic stroke. Chin Tradit Herb Drug. 2007;4:581–4.
12.
go back to reference Duan S, Wang T, Zhang J, Li M, Lu C, Wang L, et al. Huatuo Zaizao pill promotes functional recovery and neurogenesis after cerebral ischemia-reperfusion in rats. BMC Complement Altern Med. 2017;17(1):19.CrossRefPubMedPubMedCentral Duan S, Wang T, Zhang J, Li M, Lu C, Wang L, et al. Huatuo Zaizao pill promotes functional recovery and neurogenesis after cerebral ischemia-reperfusion in rats. BMC Complement Altern Med. 2017;17(1):19.CrossRefPubMedPubMedCentral
13.
go back to reference Wang B, Wu XY, Yu SQ, Xiang JL. Progress in pharmacological and clinical studies on HUATUO ZAIZAO PILL. Chinese traditional and herbal Drugs. 2001;32(8):762–3. Wang B, Wu XY, Yu SQ, Xiang JL. Progress in pharmacological and clinical studies on HUATUO ZAIZAO PILL. Chinese traditional and herbal Drugs. 2001;32(8):762–3.
14.
go back to reference Tian T. The efficacy of donepezil combined with Huatuo Zaizao pills in the treatment of subcortical ischemic vascular dementia. Chin J Pract Neruous Dis. 2016;19(11):110–1. Tian T. The efficacy of donepezil combined with Huatuo Zaizao pills in the treatment of subcortical ischemic vascular dementia. Chin J Pract Neruous Dis. 2016;19(11):110–1.
15.
go back to reference Liu HJ, Qin J, Lian W, Huang YQ. The clinical study of HT in treatment of vascular dementia. Chinese Traditional and Herbal Drugs. 2005;36(7):1052–4. Liu HJ, Qin J, Lian W, Huang YQ. The clinical study of HT in treatment of vascular dementia. Chinese Traditional and Herbal Drugs. 2005;36(7):1052–4.
17.
go back to reference Huang H, Ma ZC, Wang YG, Hong Q, Tan HL, Xiao CR, et al. Ferulic acid alleviates Aβ25-35- and lipopolysaccharide-induced PC12 cellular damage: a potential role in Alzheimer’s disease by PDE inhibition. Int J Clin Pharmacol Ther. 2015;53:828–37.CrossRefPubMed Huang H, Ma ZC, Wang YG, Hong Q, Tan HL, Xiao CR, et al. Ferulic acid alleviates Aβ25-35- and lipopolysaccharide-induced PC12 cellular damage: a potential role in Alzheimer’s disease by PDE inhibition. Int J Clin Pharmacol Ther. 2015;53:828–37.CrossRefPubMed
18.
go back to reference Jung JS, Yan JJ, Li HM, Sultan MT, Yu J, Lee HS, et al. Protective effects of a dimeric derivative of ferulic acid in animal models of Alzheimer’s disease. Eur J Pharmacol. 2016;782:30–4.CrossRefPubMed Jung JS, Yan JJ, Li HM, Sultan MT, Yu J, Lee HS, et al. Protective effects of a dimeric derivative of ferulic acid in animal models of Alzheimer’s disease. Eur J Pharmacol. 2016;782:30–4.CrossRefPubMed
19.
go back to reference Roy DS, Arons A, Mitchell TI, Pignatelli M, Ryan TJ, Tonegawa S. Memory retrieval by activating engram cells in mouse models of early Alzheimer’s disease. Nature. 2016;531:508–12.CrossRefPubMedPubMedCentral Roy DS, Arons A, Mitchell TI, Pignatelli M, Ryan TJ, Tonegawa S. Memory retrieval by activating engram cells in mouse models of early Alzheimer’s disease. Nature. 2016;531:508–12.CrossRefPubMedPubMedCentral
20.
go back to reference Shah SA, Yoon GH, Chung SS, Abid MN, Kim TH, Lee HY, et al. Novel osmotin inhibits SREBP2 via the AdipoR1/AMPK/SIRT1 pathway to improve Alzheimer's disease neuropathological deficits[J]. Mol Psychiatry. 2017;22(3):407–16.CrossRefPubMed Shah SA, Yoon GH, Chung SS, Abid MN, Kim TH, Lee HY, et al. Novel osmotin inhibits SREBP2 via the AdipoR1/AMPK/SIRT1 pathway to improve Alzheimer's disease neuropathological deficits[J]. Mol Psychiatry. 2017;22(3):407–16.CrossRefPubMed
21.
go back to reference Lachén-Montes M, González-Morales A, de Morentin XM, Pérez-Valderrama E, Ausín K, Zelaya MV, et al. An early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease[J]. J Proteome. 2016;148:149–58.CrossRef Lachén-Montes M, González-Morales A, de Morentin XM, Pérez-Valderrama E, Ausín K, Zelaya MV, et al. An early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease[J]. J Proteome. 2016;148:149–58.CrossRef
22.
go back to reference Luo G, Xu H, Huang Y, Mo D, Song L, Jia B, et al. Deposition of BACE-1 protein in the brains of APP/PS1 double transgenic mice[J]. Biomed Res Int. 2016;2016:8380618.PubMedPubMedCentral Luo G, Xu H, Huang Y, Mo D, Song L, Jia B, et al. Deposition of BACE-1 protein in the brains of APP/PS1 double transgenic mice[J]. Biomed Res Int. 2016;2016:8380618.PubMedPubMedCentral
23.
go back to reference Aso E, Lomoio S, López-González I, Joda L, Carmona M, Fernández-Yagüe N, et al. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer’s disease. Brain Pathol. 2012;22(5):636–53.CrossRefPubMed Aso E, Lomoio S, López-González I, Joda L, Carmona M, Fernández-Yagüe N, et al. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer’s disease. Brain Pathol. 2012;22(5):636–53.CrossRefPubMed
24.
go back to reference Almutairi MM, Alanazi WA, Alshammari MA, Alotaibi MR, Alhoshani AR, Al-Rejaie SS, et al. Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model. BMC Complement Altern Med. 2017;17(1):472.CrossRefPubMedPubMedCentral Almutairi MM, Alanazi WA, Alshammari MA, Alotaibi MR, Alhoshani AR, Al-Rejaie SS, et al. Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model. BMC Complement Altern Med. 2017;17(1):472.CrossRefPubMedPubMedCentral
25.
go back to reference Yu L, Wang S, Chen X, Yang H, Li X, Xu Y, et al. Orientin alleviates cognitive deficits and oxidative stress in Abeta1-42-induced mouse model of Alzheimer’s disease. Life Sci. 2015;121:104–9.CrossRefPubMed Yu L, Wang S, Chen X, Yang H, Li X, Xu Y, et al. Orientin alleviates cognitive deficits and oxidative stress in Abeta1-42-induced mouse model of Alzheimer’s disease. Life Sci. 2015;121:104–9.CrossRefPubMed
26.
27.
go back to reference Hui Z, Sha DJ, Wang SL, Li CS, Qian J, Wang JQ, et al. Panaxatriol saponins promotes angiogenesis and enhances cerebral perfusion after ischemic stroke in rats. BMC Complement Altern Med. 2017;17(1):70.CrossRefPubMedPubMedCentral Hui Z, Sha DJ, Wang SL, Li CS, Qian J, Wang JQ, et al. Panaxatriol saponins promotes angiogenesis and enhances cerebral perfusion after ischemic stroke in rats. BMC Complement Altern Med. 2017;17(1):70.CrossRefPubMedPubMedCentral
28.
go back to reference Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A. 2009;106(39):16877–82.CrossRefPubMedPubMedCentral Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A. 2009;106(39):16877–82.CrossRefPubMedPubMedCentral
29.
go back to reference Fol R, Braudeau J, Ludewig S, Abel T, Weyer SW, Roederer JP, et al. Viral gene transfer of APPs alpha rescues synaptic failure in an Alzheimer’s disease mouse model. Acta Neuropathol. 2016;131:247–66.CrossRefPubMed Fol R, Braudeau J, Ludewig S, Abel T, Weyer SW, Roederer JP, et al. Viral gene transfer of APPs alpha rescues synaptic failure in an Alzheimer’s disease mouse model. Acta Neuropathol. 2016;131:247–66.CrossRefPubMed
30.
go back to reference Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.CrossRefPubMed Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.CrossRefPubMed
31.
go back to reference Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 2001;56(1):127–9.CrossRefPubMed Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 2001;56(1):127–9.CrossRefPubMed
32.
go back to reference Reitz C. Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. 2012;2012:369808. Reitz C. Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. 2012;2012:369808.
33.
go back to reference Alzheimer’s Association. 2010 Alzheimer’s disease facts and figures. Alzheimers Dement. 2010;6(2):158–94.CrossRef Alzheimer’s Association. 2010 Alzheimer’s disease facts and figures. Alzheimers Dement. 2010;6(2):158–94.CrossRef
34.
go back to reference Golde TE. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005;15(1):84–7.CrossRefPubMed Golde TE. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005;15(1):84–7.CrossRefPubMed
35.
go back to reference Singh S, Kushwah AS, Singh R, Farswan M, Kaur R. Current Therapeutic strategy in Alzheimer’ s disease. Eur Rev Med Pharmacol Sci. 2012;16(12):1651–64.PubMed Singh S, Kushwah AS, Singh R, Farswan M, Kaur R. Current Therapeutic strategy in Alzheimer’ s disease. Eur Rev Med Pharmacol Sci. 2012;16(12):1651–64.PubMed
36.
go back to reference Miners JS, Barua N, Kehoe PG, Gill S, Love S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol. 2011;70(11):944–59.CrossRefPubMed Miners JS, Barua N, Kehoe PG, Gill S, Love S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol. 2011;70(11):944–59.CrossRefPubMed
37.
go back to reference Lok K, Zhao H, Shen H, Wang Z, Gao X, Zhao W, et al. Characterization of APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background. Neurosci Lett. 2013;557:84–9.CrossRefPubMed Lok K, Zhao H, Shen H, Wang Z, Gao X, Zhao W, et al. Characterization of APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background. Neurosci Lett. 2013;557:84–9.CrossRefPubMed
38.
go back to reference Reiserer RS, Harrison FE, Syverud DC. Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 2007;6(1):54–65.CrossRefPubMed Reiserer RS, Harrison FE, Syverud DC. Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 2007;6(1):54–65.CrossRefPubMed
39.
go back to reference Zhang H, Wang P, Xue Y, Liu L, Li Z, Liu Y. Allicin ameliorates cognitive impairment in APP/PS1 mice via suppressing oxidative stress by blocking JNK signaling pathways. Tissue Cell. 2018;50:89–95.CrossRefPubMed Zhang H, Wang P, Xue Y, Liu L, Li Z, Liu Y. Allicin ameliorates cognitive impairment in APP/PS1 mice via suppressing oxidative stress by blocking JNK signaling pathways. Tissue Cell. 2018;50:89–95.CrossRefPubMed
40.
go back to reference Lømo T. The discovery of long-term potentiation. Philos Trans R Soc B Biol Sci. 2003;358(1432):617–20.CrossRef Lømo T. The discovery of long-term potentiation. Philos Trans R Soc B Biol Sci. 2003;358(1432):617–20.CrossRef
41.
42.
go back to reference Rowan MJ, Klyubin I, Cullen WK, Anwyl R. Synaptic plasticity in animal models of early Alzheimer’s disease. Philos Trans R Soc Lond Ser B Biol Sci. 2003;358:821–8.CrossRef Rowan MJ, Klyubin I, Cullen WK, Anwyl R. Synaptic plasticity in animal models of early Alzheimer’s disease. Philos Trans R Soc Lond Ser B Biol Sci. 2003;358:821–8.CrossRef
43.
go back to reference Thathiah A, De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer’s disease. Nat Rev Neurosci. 2011;12(2):73–87.CrossRefPubMed Thathiah A, De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer’s disease. Nat Rev Neurosci. 2011;12(2):73–87.CrossRefPubMed
44.
go back to reference Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010;29(17):3020–32.CrossRefPubMedPubMedCentral Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010;29(17):3020–32.CrossRefPubMedPubMedCentral
45.
go back to reference Xie H, Xiao Z, Huang J. C6 glioma-secreted NGF and FGF2 regulate neuronal APP processing through up-regulation of ADAM10 and down-regulation of BACE1, respectively. J Mol Neurosci. 2016;59(3):334–42.CrossRefPubMed Xie H, Xiao Z, Huang J. C6 glioma-secreted NGF and FGF2 regulate neuronal APP processing through up-regulation of ADAM10 and down-regulation of BACE1, respectively. J Mol Neurosci. 2016;59(3):334–42.CrossRefPubMed
46.
go back to reference Yuan XZ, Sun S, Tan CC, Yu JT, Tan L. The role of ADAM10 in Alzheimer’s Disease. J Alzheimers Dis. 2017;58(2):303–22. Yuan XZ, Sun S, Tan CC, Yu JT, Tan L. The role of ADAM10 in Alzheimer’s Disease. J Alzheimers Dis. 2017;58(2):303–22.
47.
go back to reference Marcello E, Epis R, Saraceno C, Gardoni F, Borroni B, Cattabeni F, et al. SAP97-mediated local trafficking is altered in Alzheimer disease patients’ hippocampus. Neurobiol Aging. 2012;33(2):422. e1–422. e10.CrossRef Marcello E, Epis R, Saraceno C, Gardoni F, Borroni B, Cattabeni F, et al. SAP97-mediated local trafficking is altered in Alzheimer disease patients’ hippocampus. Neurobiol Aging. 2012;33(2):422. e1–422. e10.CrossRef
48.
go back to reference Lleo A, Saura CA. γ-secretase substrates and their implications for drug development in Alzheimer’s disease. Curr Top Med Chem. 2011;11(12):1513–27.CrossRefPubMed Lleo A, Saura CA. γ-secretase substrates and their implications for drug development in Alzheimer’s disease. Curr Top Med Chem. 2011;11(12):1513–27.CrossRefPubMed
49.
go back to reference Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. γ-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci. 2003;100(11):6382–7.CrossRefPubMedPubMedCentral Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. γ-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci. 2003;100(11):6382–7.CrossRefPubMedPubMedCentral
50.
go back to reference Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422(6930):438–44.CrossRefPubMed Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422(6930):438–44.CrossRefPubMed
51.
go back to reference Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, et al. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci. 2005;25(29):6755–64.CrossRefPubMed Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, et al. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci. 2005;25(29):6755–64.CrossRefPubMed
52.
go back to reference Dewachter I, Reverse D, Caluwaerts N, Ris L, Kuiperi C, Van den Haute C, et al. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci. 2002;22(9):3445–53.CrossRefPubMed Dewachter I, Reverse D, Caluwaerts N, Ris L, Kuiperi C, Van den Haute C, et al. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci. 2002;22(9):3445–53.CrossRefPubMed
53.
go back to reference Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, et al. Cilostazol suppresses beta-amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1 coupled retinoic acid receptor-beta. J Neurosci Res. 2014;92(11):1581–90.CrossRefPubMed Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, et al. Cilostazol suppresses beta-amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1 coupled retinoic acid receptor-beta. J Neurosci Res. 2014;92(11):1581–90.CrossRefPubMed
54.
go back to reference Tachida Y, Nakagawa K, Saito T, Saido TC, Honda T, Saito Y, et al. Interleukin-1 beta up regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. J Neurochem. 2008;104(5):1387–93.CrossRefPubMed Tachida Y, Nakagawa K, Saito T, Saido TC, Honda T, Saito Y, et al. Interleukin-1 beta up regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. J Neurochem. 2008;104(5):1387–93.CrossRefPubMed
55.
go back to reference Tsai FS, Wu LY, Yang SE, Cheng HY, Tsai CC, Wu CR, et al. Ferulic acid reverses the cognitive dysfunction caused by amyloid β peptide 1-40 through anti-oxidant activity and cholinergic activation in rats. Am J Chin Med. 2015;43(2):319–35.CrossRefPubMed Tsai FS, Wu LY, Yang SE, Cheng HY, Tsai CC, Wu CR, et al. Ferulic acid reverses the cognitive dysfunction caused by amyloid β peptide 1-40 through anti-oxidant activity and cholinergic activation in rats. Am J Chin Med. 2015;43(2):319–35.CrossRefPubMed
Metadata
Title
Huatuo Zaizao pill ameliorates cognitive impairment of APP/PS1 transgenic mice by improving synaptic plasticity and reducing Aβ deposition
Authors
Jing-Hua Zhang
Lin-Jie Yu
Hui Yang
Zhen Hui
Su Jiang
Ling Chen
Yang Zhao
Su-Lei Wang
Yi Liu
Yun Xu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2018
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-018-2237-2

Other articles of this Issue 1/2018

BMC Complementary Medicine and Therapies 1/2018 Go to the issue